Events

EASDec 2016 and EUROCONDOR 6th General Assembly - June 22nd-25th, Manchester, UK

Celebrated in Manchester, UK at the end of june, the Annual Meeting of the European Association for the Study of Diabetes Eye Complications study Group also hosted the 6th and final General Assembly of our project. During the EUROCONDOR sessions, held on Wednesday 22nd and Thursday 23rd before the opening of the EASDec congress, all partners of the project discussed and analyzed together the main results of the 2-year clinical trial, evaluating the outcomes and preparing the key messages for communication and dissemination over the next months. During the EASDec sessions, several EUROCONDOR partners presented some research related with the project: Olga Durando (UTurin) presented "Vision related quality of life in patients with type 2 diabetes in the EUROCONDOR trial"; Angela M Valverde (CSIC) presented "Inhibition of protein tyrosine phosphatase 1B protects against inflammation‐induced gliosis in the retina"; Edoardo Midena (UPadova) presented "Hyper reflective retinal spots in diabetic eyes: the validation approach"; C Hernández (VHIR) presented "Mediators between reactive gliosis and vascular leakage in diabetic retinopathy: a proteomic approach using human retinas" and Rafael Simó gave a brief lecture on "EUROCONDOR and beyond". Read more about EUROCONDOR General Assembly/EASDec2016 in the News section below and find the full program and all details about EASDec 2016 here!


News

EUROCONDOR Final General Assembly and EASDec 2016

The EUROCONDOR project held its 6th and final General Assembly on Wednesday 22nd and Thursday 23rd of June 2016 at Citylabs facilities in Manchester, U.K. right before the beginning of the EASDec 2016 (annual meeting of the European Association for the Study of Diabetes Eye Complications). The main purpose of this European-funded research project was to implement a clinical trial of 2 years of follow-up, with the main objective to determine whether an innovative, non-invasive treatment, was able to prevent or arrest the onset and early development of Diabetic Retinopathy (DR), the main complication of Diabetes and a major cause of sight-loss among the adult population. All EUROCONDOR partners expected this last annual meeting with excitement, as the main results were to be discussed between all delegates. The project coordinator, partner VHIR (Barcelona, Spain), and the clinical trial coordinator, partner AIBILI (Coimbra, Portugal), together with the Work Package Leaders, shared the data and results of the statistical analysis, as well as the first conclusions, so they could be openly debated and balanced with the insights of the principal investigators (PIs) from all the project sites. Over the first session, after an overview of the Clinical Trial and a synthesis of the findings on the mechanism of action of neuroprotection in early DR, the long-expected, freshly-issued results were finally released internally to the Consortium. During the first session, the primary (efficacy of the two selected neuroprotective drugs) and secondary endpoints(such as biomarkers and predictive factors) were presented, followed by an overview on Adverse Events and vision-related Quality of Life. The second session began with a talk about the project impact and perspectives ran by the project coordinator Professor Rafael Simó, in order to define some key messages and outcomes. This was followed by a synthesis on the management tasks for the closure and final reporting of the project to the European Commission by project manager Eila van Reck. Finally, Professor Simon Harding (partner UOL, Liverpool, U.K.), presented the main planned Dissemination and Communication activities for the months to come. Among these: several publications in high-impact peer-reviewed journals (summer and autumn 2016); the official presentation of the results to international congresses in both Diabetes and Vision/Ophthalmology (spring 2017) and some activities aimed at the general public, healthcare professionals and the Diabetes community at large, including patients' associations and advocacy groups (with the collaboration of partner IDF-Europe, Brussels, Belgium). In particular, all eleven clinical sites were invited to host a specific meeting aimed at the patients who took part in the trial, their hospital staff and families, so they could hear about the results and the outcomes of the project they were involved in. After the General Assembly, some partners also took part in the EASDec 2016, held on June 23rd to 25th. They could seize this opportunity to present part of the body of work of the EUROCONDOR project, either through lectures or posters (see the whole program of EASDec2016 here). As the coordinator of the project, Professor Simó gave a short talk on "EUROCONDOR and beyond", aimed at presenting the project, its outcomes and some of its most exciting perspectives. The joint event of EUROCONDOR final General Assembly and EASDec2016 was also a fantastic opportunity to count with the presence of Professor Thomas W. Gardner, M.D.-M.S. from the University of Michigan, Kellogg Eye Center - Ann Arbor. As one of the world-leading experts in Diabetic Retinopathy and a member of the External Scientific Advisory Board of EUROCONDOR, Prof. Gardner was invited to both take part in the EUROCONDOR sessions and to give the Eva Kohner lecture at EASDec 2016 on Friday 24th. The inspiring talk he shared with Dr. Jeffrey M. Sundstrom, from Penn State Hershey Eye Center: "A proposal for early and personalised treatment of Diabetic Retinopathy", was certainly one of the highlights of this edition of EASDec meeting. The presence of Professor Eva Kohner herself, together with the evocation by Prof. Gardner of her outstanding contribution and aura in the field of Diabetic Retinopathy since her attendance to the 1968 Airlie House Symposium, gave the lecture a genuinely moving tone and raised a warm applause. See more details on EASDec2016 here.


ARVO 2016 - May 1st to 5th - Seattle, USA.

With over 11.000 attendees, the Annual Meeting of the Association for Research in Vision and Ophthalmology is the largest gathering of eye and vision researchers in the world. Its 2016 edition was held in Seattle from May 1st to 5th. Being a major global event in vision and eye research, with about half the audience coming from all around the world (over 75 countries represented), it was critical for the visibility and impact of EUROCONDOR that the research and results could be presented and spread from this platform. Several partners lectured or presented posters during the week: - Silvia Simao (CORC, AIBILI, Coimbra, Portugal) with the poster Multifocal electroretinography to evaluate retinal function in the setting of a multicenter clinical trial, which presented the preparation of EUROCONDOR mfERG Normative Database. - Pr. Midena (UPadova, Padova, Italy) presented a poster on Hyperreflective Retinal Spots in Diabetic Eyes with and without Diabetic Macular Edema: B-Scan and en-face Spectral Domain Optical Coherence Tomography Evaluation. - Finally, the poster from Pr. Jakob Grauslund (SDU, Odense University Hospital, Odense, Denmark): Correlations between retinal vessels calibres and neurodegeneration in patients with no or mild diabetic retinopathy in the European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR) was selected by ARVO Program Committee as a Hot Topic and listed among the top 2% of posters. This great distinction provided both emphasis on Pr. Grauslund's team remarkable work, as well as extra spotlights on the EUROCONDOR project at an international level. Find the full program and all details about ARVO 2016 here!


WORLD HEALTH DAY 2016: BEAT DIABETES!

On World Health Day, April 7th 2016, we all work together to Beat Diabetes! Main goals of this global campaign are "raising awareness about the rise in diabetes" and "triggering a set of specific, effective and affordable actions to tackle diabetes, [which] will include steps to prevent diabetes and diagnose, treat and care for people with diabetes". Both match our project's objectives: by studying and preventing the onset of Diabetic Retinopathy (the main and most feared complication of diabetes), EUROCONDOR aims at improving the lives of millions of people living with diabetes. Results are expected in June 2016: follow the latest news with #WHD2016 and #EUROCONDOR, or learn more about the project within these pages.


Merry Christmas and a Happy New Year 2016!

In this Christmas time, EUROCONDOR's Coordination Team (VHIR) would like to extend their warmest wishes to all partners. We also want to thank you all for your continued effort and dedication to the project during the past four years: none of what has been done so far would have been possible without such a strong and committed Consortium! We would like to acknowledge here the daily work, effort and enthousiasm of all the personnel involved in EUROCONDOR and wish you all a Happy New Year 2016: inspiring, full of opportunities and exciting challenges! And of course, a great conclusion of our common project!


World Diabetes Congress (#WDC 2015) in Vancouver - Nov. 30th - Dec. 4th

This 2015 edition of the World Diabetes Congress (WDD), took place in Vancouver, Canada, from November 30th to December 4th. With around 12.000 attendants and over 300 speakers, WDC is the premier global diabetes meeting, which unites the global diabetes community in order to promote dissemination and promotion of leading scientific advances and knowledge on practical aspects related to diabetes care, education and advocacy. Participants to WDC include physicians, scientists, nurses, educators and other healthcare professionals, together with government representatives, policy makers, IDF Member Associations and the global press. Find more about WDC here


World Diabetes Day (#WDD 2015) - November 14th

As every year, November 14th was World Diabetes Day (WDD), the first and largest global awareness campaign on Diabetes. It was created by the International Diabetes Federation (IDF) and the World Health Organization (WHO) back in 1991 and now involves people, healthcare professionals, institutions, associations and NGOs from 160+ countries: the 2014 edition reached over 1 billion people worldwide! The official logo of WDD - a blue circle - represents the awareness and unity of the global diabetes community in response to the epidemic. Diabetic Retinopathy (DR), an ophthalmologic disease, is the most common and most feared complication of Diabetes. It is also the first cause of blindness among working-age population in developped countries. The medical, social and economic burden of DR is huge and, even though effective, current treatments are expensive, invasive while having significant side effect. With the aim to improve the lives of millions of people living with Diabetes, the EUROCONDOR project is studying an innovative, non-invasive treatment to prevent the early development of Diabetic Retinopathy (DR). Its one-of-a-kind 2-year clinical trial was completed at the beginning of November, whith results expected as soon as March 2016. With the successful end of our Clinical Trial, most of the 17 partners of EUROCONDOR joined the WDD campaign to raise awareness on both Diabetes and our project, through their own websites, social media platforms or local press! Our partner IDF-Europe also represented the project at the European Parliament through their actions and distributed our information leaflets. Follow the latest news on our project among the pages of EUROCONDOR website...


EVER 2015 Congress - Nice, France, October 7th to 10th

This year's edition of the EVER (European Association for Vision and Eye Research) Congress took place in Nice. Considered the leading European association for ophthalmologic research, EVER currently counts with more than 850 members from about 50 countries around the world. The congress hosted lectures from several members of the EUROCONDOR Consortium, from the University of Padova (Dr. Vujosevic and Pr. Midena) and VHIR, Barcelona (Drs. Simó and Hernández). Moreover, Dr. S. Vujosevic together with Dr. J. Ferreira (Lisbon Central Hospital Centre) organized a session called "Diabetic Retinopathy: a neurodegenerative disease", which addressed very specifically the innovative focus and rationale of the EUROCONDOR project. Check the EVER 2015 webpage for the whole program and the abstracts of the EUROCONDOR Consortium members' presentations.


WORLD SIGHT DAY - OCTOBER 8th 2015

Thursday October 8th was World Sight Day, a global annual event to focus attention worldwide on vision impairment and blindness. This year's call for action was EYE CARE FOR ALL! Just a few weeks away from completing its 2-year Clinical Trial (Last Patient Last Visit is scheduled by the end of October 2015), the EUROCONDOR project aims at improving the lives of millions of patients living with diabetes, by preventing the development of Diabetic Retinopathy (DR), the most common complication of diabetes and the leading cause of blindness among the working-age population in developed countries. Check eurocondor.eu for more information and follow #WorldSightDay 2015 online wordwide.


15TH EURETINA Congress - Nice 2015

This year's edition of the EURETINA (European society of Retina Specialists) Congress took place in Nice, France, from September 17th to 20th. As part of the EVICR.net Retina Clinical Trials session, Pr. Simon Harding from the University of Liverpool (and leader of EUROCONDOR's dissemination board) presented our project and its 2-year Clinical Trial, which involved 450 patients from 11 Hospitals across Europe. His lecture, "EUROCONDOR Clinical Trial: neuroprotection for non-proliferative diabetic retinopathy", gave the attendants a comprehensive and updated summary, at a very strategic time for the Consortium, a couple of months after our 5th General Assembly and a few weeks before the end of the Clinical Trial (scheduled at the end of October 2015). Check the EURETINA 2015 webpage for the whole scientific program.


Partner IDF-Europe represents EUROCONDOR at the 51st EASD Congress in Stockholm, 14-18 September 2015

The 51st annual congress of the European Association for the Study of Diabetes took place in the Swedish capital from September 14th to 18th 2015. As a key-partner for the communication and visibility of EUROCONDOR, IDF-Europe set up their stand at the Congress and represented our project, raising awareness and distributing our leaflets and specially updated one-pager. For more information about EASD's annual congress, click here.


2015 EASDec Meeting, Turin, 26-28 June 2015

The 2015 meeting of the Eye Study Group of the EASD was held in Turin from June 26th to June 28th. Syddansk Universitet presented the Baseline data from EUROCONDOR at the meeting. Click here for more information on the event and to read the whole program of lectures.


EUROCONDOR Annual Meeting, Turin, June 26th 2015

This year, the EUROCONDOR partners held their 5th General Assembly in Turin. As a satellite of the EASDec 2015 congress, this Annual Meeting was held in the Aula Magna lecture room of the Cavallerizza Reale, an iconic architectural complex from the mid XVIIIth century. The lectures and presentations gave all partners a chance to review together the progress of the project and its 2-year one-of-a-kind Clinical Trial. But it was also a great opportunity to get a preview on some preliminary results and to plan ahead for the final year of the project, as the Clinical Trial will be completed by the end of October 2015. This will allow most of the data analysis to be performed during the winter, and the final results to come by March 2016. In parallel, a comprehensive body of basic research is being performed in order to study how the candidate neuro-protective drugs exert their preventive/therapeutic effects. Check EUROCONDOR website for all news and updates!


EUROCONDOR at 2015 BIO International Convention

BCN Peptides, one of EUROCONDOR partners, attended the 2015 BIO International Convention. Celebrated in Philadelphia, from June 15th to 18th, it is the world's largest biotechnology gathering. Aside from giving visibility to the EUROCONDOR project, BCN Peptides explored partnership opportunities and potential outcomes for Somatostatin eyedrops. They held meetings and interviews with 15 companies, 5 of which had already showed interest and 10 were new contacts in the Pharmaceutical sector. No less than 6 of them are from the U.S (where almost 30 millions of people were suffering from Diabetes in 2014) and 7 from Asia (mainly Japan (4), Korea and China), 1 from Brasil and 1 from Europe. Among these, EUROCONDOR's therapeutic perspectives attracted 2 of the top-ten companies in the Pharmaceutical sector. Find out more about 2015 Bio International Convention here.


Combating vision loss: an inside view of EUROCONDOR

In a recent article published by the International Diabetes Federation Europe (IDF Europe), Prof Peter Scanlon, Consultant Ophthalmogist, and Elena Beltramo, Basic Researcher, explain what the research project is all about and why they strive to achieve one common goal: find a new and less invasive treatment for the early stages of diabetic retinopathy, and allow people with diabetes to preserve their sight. Click here to read the whole story.


Prof Simó shares views on diabetic retinopathy

Prof Simó was a guest speaker on diabetic retinopathy at REDDSTAR's exploitation workshop on 21 October 2014. The REDDSTAR project looks at how stromal cell therapy can be used to treat diabetes and prevent complications. In this context, and presenting the EUROCONDOR research, Prof Simó helped the consortium explore opportunities for further research and use of REDDSTAR's findings as part of a group of experts on 6 diabetes complications, including nephropathy and retinopathy. Click here for more information.


EUROCONDOR partners take stock of project's progress at 4th Annual Meeting

Partners of the EUROCONDOR consortium met earlier this 17 May 2014 at the Military Hospital in Padova (Italy) for the 4th General Assembly of the EU-funded research project, which looks at preventing or stopping the development of diabetic retinopathy using an innovative treatment using eye-drops. The therapeutic strategy of the project is based on neuroprotection to prevent or arrest retinal neurodegeneration in early stages of the disease. The EUROCONDOR research project consists of a prospective and randomized study in 450 people living with type 2 diabetes, who will be administered two neuroprotectors therapeutic agents (somatostatin and brimonidine) through eye-drops. During the 4th Annual Meeting of the project, participants reviewed the basic research that supports the clinical trial that started in February 2013. Discussions also included an in-depth debate about the study's clinical protocol and the best way of implementing it in all participating countries.


REDDSTAR Project: Reducing diabetes complications using stem cells

REDDSTAR, Repair of Diabetic Damage by Stromal Cell Administration, is an EU-funded project which will develop and test bone marrow derived stromal cell therapy to treat diabetes mellitus. The objective is to control blood glucose while also addressing a range of six diabetes-related complications: retinopathy, nephropathy, neuropathy, diabetic cardiomyopathy, impaired bone fracture repair and diabetic foot ulcers. Click here to find out more.


Visit the IDF Europe Newsroom for the latest news on European research on diabetes in Europe

IDF Europe, partner of EUROCONDOR, has built an online platform - the IDF Europe Newsroom - to share the latest developments of research projects in the field of diabetes and chronic diseases. The newsroom also gives visitors a round-up of all the activities carried out by diabetes associations and the wider diabetes community in Europe. Find out more on newsroom.idf-europe.org


AIBILI to present EUROCONDOR baseline data at 2014 ARVO annual meeting

The abstract submitted by AIBILI on EUROCONDOR baseline data was accepted for poster presentation at the 2014 ARVO annual meeting. AIBILI will be presenting the poster entitled "Baseline data of the EUROCONDOR Project (EC-FP7-278040) to assess neurovascular changes and the efficacy of neuroprotective drugs administered topically to prevent or arrest diabetic retinopathy (DR)". Find out more about the event.


Prof. Simó gives an update on EUROCONDOR at 2014 Euretina Winter Meeting

The 4th Euretina Winter Meeting was held in Rome on 25 January 2014. Prof. Rafael Simó took part in the event and gave an update on the EUROCONDOR research project with a presentation on the "Metabolic fingerprints of proliferative diabetic retinopathy". Find out more about the event.


EUROCONDOR project on EU research online portal HorizonHealth.eu

EUROCONDOR recently joined the EU online portal "HorizonHealth.eu". Launched in March 2013, the portal aims at promoting European research projects to journalists and European citizens by making them more accessible through a user-friendly and interactive platform. You can check Eurocondor's profile on the HorizonHealth platform here.


EUROCONDOR clinical trial to begin in February 2013

Clinical trial to test the safety and effectiveness of a new therapeutic treatment to combat diabetic retinopathy will begin early February 2013 in several clinical centres across the EU as part of the EUROCONDOR project. EUROCONDOR, the European Consortium for the Early Treatment of Diabetic Retinopathy (DR), will implement the first clinical trial using eye drops for the treatment of the earliest stages of this diabetes-related complication. Diabetic retinopathy is an eye disease that occurs in people living with diabetes which can ultimately lead to severe loss of vision or even blindness. For more information, contact Eila van Reck at eila.van_reck@vhir.org


EUROCONDOR in Parliament Magazine - November 2012

The Parliament Magazine, a publication of record for politics and policy amongst MEPs and EU stakeholders, featured an article on the EUROCONDOR project, coinciding with World Diabetes Day (14 November). Click here to read the article.